Agile Therapeutics, Inc.
Agile Therapeutics, Inc. (AGRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
agrx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Agile Therapeutics, Inc.You AGRX | $10M | N/A | — | -$6.71 |
 Biofrontera AG BFFTF | $19M | N/A | — | -$13.02 |
 RIV Capital Inc. CNPOF | $11M | N/A | — | -$0.59 |
 The Flowr Corporation FLWPF | $0M | N/A | — | -$0.23 |
 Guardion Health Sciences, Inc. GHSI | $4M | 42.94x | — | $0.12 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Agile Therapeutics, Inc. (AGRX) measures how much investors pay for each dollar of the company's trailing earnings. AGRX's current PE ratio of N/A is calculated by dividing its stock price of $1.51 by its TTM earnings per share of -$6.71.
Frequently asked questions
AGRX pe ratio · 6 questionsAGRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.51 and TTM EPS of -$6.71. Data sourced from Financial Modeling Prep via AGRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Agile Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09